Cerebrolysin
FPF-1070 / Brain-Derived Peptide Preparation
Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.
Mecanismo de Ação
Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.
Protocolos de Pesquisa
Para fins de pesquisa apenas. Não é conselhos médicos.
Clinical protocols use 10-30ml IV infusion daily for 10-20 day cycles. Repeated every 3-6 months. Some protocols use 5-10ml intramuscularly. Not a single peptide — it is a standardized mixture.
Notas de Pesquisa
Clinical Research Status
Cerebrolysin has been studied in numerous randomized controlled trials for acute ischemic stroke, traumatic brain injury, and vascular dementia. The CASTA trial and other large studies have shown mixed results, with some demonstrating improved functional outcomes while others failed to reach primary endpoints. It remains one of the most extensively studied neuropeptide preparations globally despite lacking FDA approval.
Key Published Findings
Research demonstrates neurotrophic activity similar to naturally occurring nerve growth factors, promoting neuronal sprouting, synaptic formation, and neurogenesis. Studies in Alzheimer's disease patients have shown improvements in cognitive function and global clinical assessments over 6-month treatment periods. Animal models consistently demonstrate reduced infarct volume and improved behavioral outcomes following induced stroke.
Safety Profile
The most common adverse effects include headache, dizziness, and injection site reactions, with serious adverse events occurring at rates similar to placebo in controlled trials. Allergic reactions are possible due to the porcine-derived nature of the product, though anaphylaxis is rare. It is contraindicated in patients with epilepsy, severe renal impairment, and known hypersensitivity to porcine proteins.
Comparison to Related Compounds
Unlike single-peptide nootropics such as Semax or Selank, Cerebrolysin is a complex mixture containing multiple bioactive fragments that may act synergistically on various neurotrophic pathways. Cortexin is a similar porcine brain-derived preparation but with distinct manufacturing processes and somewhat different peptide profiles. Compared to synthetic nootropics, Cerebrolysin's multi-target mechanism may offer broader neuroprotection but complicates mechanistic understanding.
Community Observations
Users frequently report improved mental clarity, enhanced recovery from brain injuries, and better cognitive function during treatment cycles. The requirement for IV/IM administration limits self-experimentation, and many users travel to countries where it is available over-the-counter. Cost and accessibility remain significant barriers, with some users sourcing from Eastern European or Asian pharmacies.
Meio-Vivo
~Minutes (component peptides); neurotrophic effects last hours
Reconstituição
Pre-mixed injectable solution (no reconstitution)
Armazenamento
Liofilizado
Room temperature up to 25C. Protect from light.
Reconstituído
Use immediately after opening ampule. Single-use only.
Situação Legal nos EUA
Também Conhecido Como
Perguntas frequentes
O que é Cerebrolysin?
Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.
Como Cerebrolysin funciona?
Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.
Qual é o status regulatório de Cerebrolysin nos EUA?
Not FDA-approved (approved in 40+ other countries)
Qual é a meia-vida de Cerebrolysin?
~Minutes (component peptides); neurotrophic effects last hours
Por quais outros nomes Cerebrolysin é conhecido?
FPF-1070, Brain-Derived Peptide Preparation
Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.
Leia a declaração completa